BACKGROUND: Cognition is increasingly being recognized as an important aspect of psychotic disorders and a key contributor to functional outcome. In the past, comparative studies have been performed in schizophrenia and schizo-affective disorder with regard to cognitive performance, but the results have been mixed and the cognitive measures used have not always assessed the cognitive deficits found to be specific to psychosis. A set of optimized cognitive paradigms designed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia (CNTRACS) Consortium to assess deficits specific to schizophrenia was used to measure cognition in a large group of individuals with schizophrenia and schizo-affective disorder. METHOD: A total of 519 participants (188 with schizophrenia, 63 with schizo-affective disorder and 268 controls) were administered three cognitive paradigms assessing the domains of goal maintenance in working memory, relational encoding and retrieval in episodic memory and visual integration. RESULTS: Across the three domains, the results showed no major quantitative differences between patient groups, with both groups uniformly performing worse than healthy subjects. CONCLUSIONS: The findings of this study suggests that, with regard to deficits in cognition, considered a major aspect of psychotic disorder, schizophrenia and schizo-affective disorder do not demonstrate major significant distinctions. These results have important implications for our understanding of the nosological structure of major psychopathology, providing evidence consistent with the hypothesis that there is no natural distinction between cognitive functioning in schizophrenia and schizo-affective disorder.
BACKGROUND: Cognition is increasingly being recognized as an important aspect of psychotic disorders and a key contributor to functional outcome. In the past, comparative studies have been performed in schizophrenia and schizo-affective disorder with regard to cognitive performance, but the results have been mixed and the cognitive measures used have not always assessed the cognitive deficits found to be specific to psychosis. A set of optimized cognitive paradigms designed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia (CNTRACS) Consortium to assess deficits specific to schizophrenia was used to measure cognition in a large group of individuals with schizophrenia and schizo-affective disorder. METHOD: A total of 519 participants (188 with schizophrenia, 63 with schizo-affective disorder and 268 controls) were administered three cognitive paradigms assessing the domains of goal maintenance in working memory, relational encoding and retrieval in episodic memory and visual integration. RESULTS: Across the three domains, the results showed no major quantitative differences between patient groups, with both groups uniformly performing worse than healthy subjects. CONCLUSIONS: The findings of this study suggests that, with regard to deficits in cognition, considered a major aspect of psychotic disorder, schizophrenia and schizo-affective disorder do not demonstrate major significant distinctions. These results have important implications for our understanding of the nosological structure of major psychopathology, providing evidence consistent with the hypothesis that there is no natural distinction between cognitive functioning in schizophrenia and schizo-affective disorder.
Authors: Deanna M Barch; Cameron S Carter; Steve C Dakin; James Gold; Steven J Luck; Angus Macdonald; John D Ragland; Steven Silverstein; Milton E Strauss Journal: Schizophr Bull Date: 2011-11-17 Impact factor: 9.306
Authors: John D Ragland; Roshan Cools; Michael Frank; Diego A Pizzagalli; Alison Preston; Charan Ranganath; Anthony D Wagner Journal: Schizophr Bull Date: 2008-10-16 Impact factor: 9.306
Authors: Daniel H Mathalon; Ralph E Hoffman; Todd D Watson; Ryan M Miller; Brian J Roach; Judith M Ford Journal: Front Hum Neurosci Date: 2010-01-29 Impact factor: 3.169
Authors: Abraham Reichenberg; Philip D Harvey; Christopher R Bowie; Ramin Mojtabai; Jonathan Rabinowitz; Robert K Heaton; Evelyn Bromet Journal: Schizophr Bull Date: 2008-05-20 Impact factor: 9.306
Authors: Michael F Green; Pamela D Butler; Yue Chen; Mark A Geyer; Steven Silverstein; Jonathan K Wynn; Jong H Yoon; Vance Zemon Journal: Schizophr Bull Date: 2008-11-20 Impact factor: 9.306
Authors: Deanna M Barch; Cameron S Carter; James M Gold; Sheri L Johnson; Ann M Kring; Angus W MacDonald; Diego A Pizzagalli; J Daniel Ragland; Steven M Silverstein; Milton E Strauss Journal: J Abnorm Psychol Date: 2017-04-13
Authors: Brian P Keane; Gennady Erlikhman; Sabine Kastner; Danielle Paterno; Steven M Silverstein Journal: Neuropsychologia Date: 2014-11-01 Impact factor: 3.139
Authors: Julia Ermel; Cameron S Carter; James M Gold; Angus W MacDonald; J Daniel Ragland; Steven M Silverstein; Milton E Strauss; Deanna M Barch Journal: Schizophr Res Cogn Date: 2017-05-09
Authors: Jason Smucny; Deanna M Barch; James M Gold; Milton E Strauss; Angus W MacDonald; Megan A Boudewyn; J Daniel Ragland; Steven M Silverstein; Cameron S Carter Journal: Schizophr Res Date: 2019-01-28 Impact factor: 4.939
Authors: J Daniel Ragland; Xiaonan L Liu; Ashley B Williams; Laura M Tully; Tara A Niendam; Cameron S Carter; Charan Ranganath Journal: Schizophr Res Date: 2020-07-29 Impact factor: 4.939